Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rakovina Therapeutics Inc ( (TSE:RKV) ) just unveiled an update.
Rakovina Therapeutics Inc., a biopharmaceutical firm specializing in AI-driven DNA-damage response cancer therapies, is progressing a pipeline of targeted drug candidates with the goal of moving them into human clinical trials through collaborations with pharmaceutical partners. Its technology platform is designed to speed up the optimization of oncology drug candidates by using artificial intelligence to analyze and refine potential treatments.
The company has secured a 30-day extension from the TSX Venture Exchange for its previously announced non-brokered private placement, now expected to close on or before April 9, 2026. Rakovina aims to raise up to $1 million by issuing up to 8,333,334 common shares at $0.12 each, with net proceeds earmarked for near-term working capital to support ongoing corporate activities and strategic initiatives as it evaluates longer-term financing options.
More about Rakovina Therapeutics Inc
Rakovina Therapeutics Inc. is a biopharmaceutical research company focused on developing innovative cancer treatments targeting the DNA-damage response. Leveraging proprietary, AI-powered platforms, the company accelerates the review and optimization of drug candidates and has built a pipeline of distinctive DNA-damage response inhibitors aimed at advancing candidates into human clinical trials with pharmaceutical partners.
Average Trading Volume: 34,527
Technical Sentiment Signal: Sell
Current Market Cap: C$2.75M
For an in-depth examination of RKV stock, go to TipRanks’ Overview page.